Global Radiation Syndrome Treatment Market 2019-2023

放射線症候群治療の世界市場2019-2023

◆タイトル:Global Radiation Syndrome Treatment Market 2019-2023
◆商品コード:IRTNTR30225
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月8日
◆ページ数:114
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥399,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、放射線症候群治療の世界市場について調査・分析し、市場概要、市場環境、放射線症候群治療市場規模、疾患別(HSC症候群、CNS症候群、GI症候群、心血管系疾患)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・放射線症候群治療の世界市場概要
・放射線症候群治療の世界市場環境
・放射線症候群治療の世界市場動向
・放射線症候群治療の世界市場規模
・放射線症候群治療の世界市場:業界構造分析
・放射線症候群治療の世界市場:疾患別(HSC症候群、CNS症候群、GI症候群、心血管系疾患)
・放射線症候群治療の世界市場:地域別市場規模・分析
・放射線症候群治療の北米市場規模・予測
・放射線症候群治療のヨーロッパ・中東・アフリカ市場規模・予測
・放射線症候群治療のアジア太平洋市場規模・予測
・放射線症候群治療の主要国分析
・放射線症候群治療の世界市場:意思決定フレームワーク
・放射線症候群治療の世界市場:成長要因、課題
・放射線症候群治療の世界市場:競争環境
・放射線症候群治療の世界市場:関連企業情報(ベンダー分析)

109 pages, November 2018
About this market
The advent of regenerative therapy is expected to help the market grow. The global radiation syndrome treatment market has seen strong advances in terms of treatment options. The advent of regenerative medicines such as stem-cell therapy is one among such advances. In stem-cell therapy, the stem cells are taken from the patient and are re-inserted to replace the damaged cells to treat or prevent a disease. Technavio’s analysts have predicted that the radiation syndrome treatment market will register a CAGR of more than 6% by 2023.
Market Overview
Increase in nuclear testing
The increasing nuclear testing in South-East Asia in recent years has resulted in the rise in the symptoms of radiation toxicity and exposure in nearby countries. also, various scientists and pharmaceutical companies believe that the increasing testing of nuclear launches cause significant damage to the environment.
Difficult to diagnose
A major share of the global radiation syndrome treatment market is dominated by acute radiation syndrome, which is highly progressive by nature. Acute radiation effects the patients in less than 24 hours of exposure to radiation. The lack of diagnostic devices for radiation syndrome is major challenge faced by the market.
For the detailed list of factors that will drive and challenge the growth of the radiation syndrome treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Amgen and Neumedicines the competitive environment is quite intense. Factors such as the increase in nuclear testing and the advent of regenerative therapy, will provide considerable growth opportunities to radiation syndrome treatment manufactures. Amgen, Neumedicines, Partner Therapeutics, Tonix Pharmaceuticals, and Onconova Therapeutics are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. The market is expected to witness the emergence of many international and regional radiation syndrome therapeutic companies who offer therapeutics for the treatment of HSC syndrome, CNS syndrome, GI syndrome, and cardiovascular syndrome caused by radiation poisoning.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY DISEASE
• Market segmentation by disease
• Comparison by disease
• HSC syndrome – Market size and forecast 2018-2023
• CNS syndrome – Market size and forecast 2018-2023
• GI syndrome – Market size and forecast 2018-2023
• Cardiovascular syndrome – Market size and forecast 2018-2023
• Market opportunity by disease
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Neumedicines
• Onconova Therapeutics
• Partner Therapeutics
• Tonix Pharmaceuticals
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Disease – Market share 2018-2023 (%)
Exhibit 18: Comparison by disease
Exhibit 19: HSC syndrome – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: HSC syndrome – Year-over-year growth 2019-2023 (%)
Exhibit 21: CNS syndrome – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: CNS syndrome – Year-over-year growth 2019-2023 (%)
Exhibit 23: GI syndrome – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: GI syndrome – Year-over-year growth 2019-2023 (%)
Exhibit 25: Cardiovascular syndrome – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Cardiovascular syndrome – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by disease
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen – Vendor overview
Exhibit 46: Amgen – Business segments
Exhibit 47: Amgen – Organizational developments
Exhibit 48: Amgen – Geographic focus
Exhibit 49: Amgen – Segment focus
Exhibit 50: Amgen – Key offerings
Exhibit 51: Amgen – Key customers
Exhibit 52: Neumedicines – Vendor overview
Exhibit 53: Neumedicines – Business segments
Exhibit 54: Neumedicines – Organizational developments
Exhibit 55: Neumedicines – Segment focus
Exhibit 56: Neumedicines – Key offerings
Exhibit 57: Neumedicines – Key customers
Exhibit 58: Onconova Therapeutics – Vendor overview
Exhibit 59: Onconova Therapeutics – Business segments
Exhibit 60: Onconova Therapeutics – Organizational developments
Exhibit 61: Onconova Therapeutics – Segment focus
Exhibit 62: Onconova Therapeutics – Key offerings
Exhibit 63: Onconova Therapeutics – Key customers
Exhibit 64: Partner Therapeutics – Vendor overview
Exhibit 65: Partner Therapeutics – Business segments
Exhibit 66: Partner Therapeutics – Organizational developments
Exhibit 67: Partner Therapeutics – Segment focus
Exhibit 68: Partner Therapeutics – Key offerings
Exhibit 69: Partner Therapeutics – Key customers
Exhibit 70: Tonix Pharmaceuticals – Vendor overview
Exhibit 71: Tonix Pharmaceuticals – Business segments
Exhibit 72: Tonix Pharmaceuticals – Organizational developments
Exhibit 73: Tonix Pharmaceuticals – Segment focus
Exhibit 74: Tonix Pharmaceuticals – Key offerings
Exhibit 75: Tonix Pharmaceuticals – Key customers
Exhibit 76: List of abbreviations Error! Bookmark not defined.



【掲載企業】

Amgen、Neumedicines、Onconova Therapeutics、Partner Therapeutics、Tonix Pharmaceuticals

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[放射線症候群治療の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆